Balan Kannan V, Wang Yongbao, Chen Siming W, Pantazis Panayotis, Wyche James H, Han Zhiyong
Department of Pediatrics, Rainbow Babies and Children's Hospital, 11100 Euclid Avenue, Suite 3100, Case Western Reserve University, Cleveland, OH 44106, USA.
Biochem Pharmacol. 2006 Aug 28;72(5):566-72. doi: 10.1016/j.bcp.2006.05.012. Epub 2006 Jun 27.
The eukaryotic proteasome is a 26S ATP-dependent proteolytic complex, which possesses chymotrypsin-like, trypsin-like and peptidyl glutamyl peptide hydrolase (PGPH) activities, which enable the proteasome to degrade all short-lived and many long-lived proteins, and consequently regulate a myriad of activities in cells. In this study, we observed that inhibition of the proteasome, and more specifically, inhibition of the chymotrypsin-like activity of the proteasome, in MCF-7 human breast cancer cells resulted in selective down-regulation of the nuclear estrogen receptor-alpha (ERalpha). Our data indicated that estrogen had no effect, whereas the ERalpha antagonist, tamoxifen, reduced the amount of ERalpha that could be subjected to down-regulation after proteasome inhibition. Furthermore, our data demonstrated that protein synthesis was required for the down-regulation of ERalpha to occur. Collectively, these data indicate the existence of a proteasome-dependent mechanism that is utilized by MCF-7 cells to maintain a steady-state level of ERalpha.
真核生物蛋白酶体是一种26S ATP依赖性蛋白水解复合物,具有胰凝乳蛋白酶样、胰蛋白酶样和肽基谷氨酰肽水解酶(PGPH)活性,这些活性使蛋白酶体能够降解所有短命和许多长命蛋白质,从而调节细胞中的众多活动。在本研究中,我们观察到在MCF-7人乳腺癌细胞中抑制蛋白酶体,更具体地说,抑制蛋白酶体的胰凝乳蛋白酶样活性,导致核雌激素受体α(ERα)的选择性下调。我们的数据表明,雌激素没有作用,而ERα拮抗剂他莫昔芬减少了蛋白酶体抑制后可被下调的ERα量。此外,我们的数据表明,ERα的下调需要蛋白质合成。总体而言,这些数据表明MCF-7细胞利用一种蛋白酶体依赖性机制来维持ERα的稳态水平。